Takeda's Latest Investment Reflects Long-Term Shift In R&D Strategy

 
• By Mandy Jackson

The Japanese pharma's new San Diego site brings together scientists from multiple locations to identify and validate therapeutic candidates across multiple modalities to enhance Takeda's global internal and external programs.

Takeda Research bulding interior 2019
Takeda relocated its San Diego R&D groups into a single facility. • Source: Takeda

Centralizing many of its research and development scientists in a single facility is part of Takeda Pharmaceutical Co. Ltd.'s strategy to boost early R&D for internally developed and externally sourced programs across modalities.

The company has been trying to diversify its research pipeline and has been able to shift during the past four...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.